Browse CAMK1G

Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Golgi apparatus membrane Peripheral membrane protein Cell membrane Peripheral membrane protein
Domain PF00069 Protein kinase domain
Function

Calcium/calmodulin-dependent protein kinase belonging to a proposed calcium-triggered signaling cascade. In vitro phosphorylates transcription factor CREB1 (By similarity).

> Gene Ontology
 
Biological Process -
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004683 calmodulin-dependent protein kinase activity
GO:0005516 calmodulin binding
Cellular Component GO:0005954 calcium- and calmodulin-dependent protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04921 Oxytocin signaling pathway
Reactome -
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CAMK1G and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CAMK1G in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CAMK1G in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6080.313
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0530.959
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0080.226
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6690.327
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8730.462
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4030.794
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.5760.0104
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.2220.0131
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.8010.408
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.6230.466
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.0860.329
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3310.0919
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CAMK1G in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277308.2-8.20.187
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CAMK1G. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CAMK1G. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CAMK1G.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CAMK1G. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CAMK1G expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CAMK1G and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCAMK1G
Namecalcium/calmodulin-dependent protein kinase IG
Aliases CLICKIII; dJ272L16.1; CLICK3; CLICK III; caM kinase I gamma; caM kinase IG; caM-KI gamma; caMK-like CREB kin ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CAMK1G collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CAMK1G.
ID Name Drug Type Targets #Targets
DB080095-[(E)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDESmall MoleculeCAMK1G1